⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL414468 | 1.00 | — | — | |
| SCHEMBL29908244 | 0.77 | TSHR (0.45) | — | |
| SCHEMBL28919218 | 0.77 | TSHR (0.45) | — | |
| SCHEMBL9773297 | 0.73 | RAB9A (0.47) | — | |
| SCHEMBL13633759 | 0.69 | — | — | |
| SCHEMBL21737595 | 0.69 | — | — | |
| SCHEMBL434410 | 0.69 | — | — | |
| SCHEMBL11312058 | 0.69 | — | — | |
| SCHEMBL12269226 | 0.69 | — | — | |
| SCHEMBL6639232 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6248773-B1 | VISION DEFECTS | ALLERGAN SALES, INC. | 2001-06-19 | — | — | US | claimed |
| EP-1032395-A1 | CYCLOPENTANE HEPTAN(ENE)OIC ACID, 2-HETEROARYLALKENYL DERIVATIVES AS THERAPEUTIC AGENTS | Allergan Sales, Inc. (US) | 2000-09-06 | — | — | EP | claimed |
| WO-1999025358-A1 | CYCLOPENTANE HEPTAN(ENE)OIC ACID, 2-HETEROARYLALKENYL DERIVATIVES AS THERAPEUTIC AGENTS | ALLERGAN SALES, INC. (US) | 1999-05-27 | — | — | WO | claimed |
| EP-2349242-A2 | AMINO ACID SALTS OF PROSTAGLANDINS | Aerie Pharmaceuticals, Inc. (US) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010096123-A2 | AMINO ACID SALTS OF PROSTAGLANDINS | AERIE PHARMACEUTICALS, INC. (US) | 2010-08-26 | — | — | WO | disclosed |
| US-6248773-B1 | VISION DEFECTS | ALLERGAN SALES, INC. | 2001-06-19 | — | — | US | disclosed |
| US-6248773-B1 | VISION DEFECTS | ALLERGAN SALES, INC. | 2001-06-19 | — | — | US | disclosed |
| CN-1291100-A | Cyclopentane Heptan (ene) oic acid, 2-hetero arylakenyl derivatives and therapeutic agents | ALLERGEN SALES INC (US) | 2001-04-11 | — | — | CN | disclosed |
| US-6160129-A | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents | ALLERGAN SALES, INC. (US) | 2000-12-12 | — | — | US | disclosed |
| US-6160129-A | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents | ALLERGAN SALES, INC. (US) | 2000-12-12 | — | — | US | disclosed |
| US-6124344-A | FOR TREATING OCULAR HYPERTENSION, GLAUCOMA | ALLERGAN SALES, INC. | 2000-09-26 | — | — | US | disclosed |
| US-6124344-A | FOR TREATING OCULAR HYPERTENSION, GLAUCOMA | ALLERGAN SALES, INC. | 2000-09-26 | — | — | US | disclosed |
| EP-1032395-A1 | CYCLOPENTANE HEPTAN(ENE)OIC ACID, 2-HETEROARYLALKENYL DERIVATIVES AS THERAPEUTIC AGENTS | Allergan Sales, Inc. (US) | 2000-09-06 | — | — | EP | disclosed |
| EP-1032395-A1 | CYCLOPENTANE HEPTAN(ENE)OIC ACID, 2-HETEROARYLALKENYL DERIVATIVES AS THERAPEUTIC AGENTS | Allergan Sales, Inc. (US) | 2000-09-06 | — | — | EP | disclosed |
| WO-1999025358-A1 | CYCLOPENTANE HEPTAN(ENE)OIC ACID, 2-HETEROARYLALKENYL DERIVATIVES AS THERAPEUTIC AGENTS | ALLERGAN SALES, INC. (US) | 1999-05-27 | — | — | WO | disclosed |
| WO-1999025358-A1 | CYCLOPENTANE HEPTAN(ENE)OIC ACID, 2-HETEROARYLALKENYL DERIVATIVES AS THERAPEUTIC AGENTS | ALLERGAN SALES, INC. (US) | 1999-05-27 | — | — | WO | disclosed |